Epidemiology of familial multiple sclerosis in Iran: a national registry-based study.
Familial multiple sclerosis
Iran
Multiple sclerosis
Sporadic multiple sclerosis
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
05 Mar 2022
05 Mar 2022
Historique:
received:
07
10
2021
accepted:
28
02
2022
entrez:
6
3
2022
pubmed:
7
3
2022
medline:
9
3
2022
Statut:
epublish
Résumé
Admittedly, little is known about the epidemiological signatures of familial multiple sclerosis (FMS) in different geographical regions of Iran. To determine the epidemiology and the risk of FMS incidence in several provinces of Iran with a different ethnic population including, Fars, Tehran, Isfahan (Persians), and Mazandaran (Mazanis), Kermanshah (Kurds), and Chaharmahal and Bakhtiari (Lors). This cross-sectional registry-based study was performed on nationwide MS registry of Iran (NMSRI) data collected from 2018 to 2021. This system, registers baseline characteristics, clinical presentations and symptoms, diagnostic and treatments at regional and national levels. A total of 9200 patients including, 7003 (76.1%) female and 2197 (23.9%) male, were participated. About 19% of patients reported a family history of MS; the order from highest to lowest FMS prevalence was as follows: Fars (26.5%), Chaharmahal and Bakhtiari (21.1%), Tehran (20.5%), Isfahan (20.3%), Mazandaran (18.0%), and Kermanshah (12.5%). Of all FMS cases, 74.7% (1308 cases) were female and 25.3% (442 cases) were male. FMS occurrence was much more common in females than males (P-value = 0.001). Further, the mean age at onset was 30 years among FMS cases. A substantially higher probability of relapsing-remitting MS and secondary-progressive MS was found among FMS cases than sporadic MS (SMS) (P_value = 0.001). There was no significant difference in Expanded Disability Status Scale (EDSS) scores between FMS and SMS. The majority of FMS cases were observed among first-degree relatives, with the highest rate in siblings. There was a significant association between MS risk and positive familial history in both maternal and paternal aunt/uncle (P_value = 0.043 and P_value = 0.019, respectively). Multiple sclerosis occurrence among offspring of females was higher than males (P_value = 0.027). In summary, our findings imply a noteworthy upward trend of FMS in Iran, even more than the global prevalence, which suggests a unique Atlas of FMS prevalence in this multi-ethnic population. Despite the highest rate of FMS within Persian and Lor ethnicities, no statistically significant difference was observed among the provinces.
Sections du résumé
BACKGROUND
BACKGROUND
Admittedly, little is known about the epidemiological signatures of familial multiple sclerosis (FMS) in different geographical regions of Iran.
OBJECTIVE
OBJECTIVE
To determine the epidemiology and the risk of FMS incidence in several provinces of Iran with a different ethnic population including, Fars, Tehran, Isfahan (Persians), and Mazandaran (Mazanis), Kermanshah (Kurds), and Chaharmahal and Bakhtiari (Lors).
METHODS
METHODS
This cross-sectional registry-based study was performed on nationwide MS registry of Iran (NMSRI) data collected from 2018 to 2021. This system, registers baseline characteristics, clinical presentations and symptoms, diagnostic and treatments at regional and national levels.
RESULTS
RESULTS
A total of 9200 patients including, 7003 (76.1%) female and 2197 (23.9%) male, were participated. About 19% of patients reported a family history of MS; the order from highest to lowest FMS prevalence was as follows: Fars (26.5%), Chaharmahal and Bakhtiari (21.1%), Tehran (20.5%), Isfahan (20.3%), Mazandaran (18.0%), and Kermanshah (12.5%). Of all FMS cases, 74.7% (1308 cases) were female and 25.3% (442 cases) were male. FMS occurrence was much more common in females than males (P-value = 0.001). Further, the mean age at onset was 30 years among FMS cases. A substantially higher probability of relapsing-remitting MS and secondary-progressive MS was found among FMS cases than sporadic MS (SMS) (P_value = 0.001). There was no significant difference in Expanded Disability Status Scale (EDSS) scores between FMS and SMS. The majority of FMS cases were observed among first-degree relatives, with the highest rate in siblings. There was a significant association between MS risk and positive familial history in both maternal and paternal aunt/uncle (P_value = 0.043 and P_value = 0.019, respectively). Multiple sclerosis occurrence among offspring of females was higher than males (P_value = 0.027).
CONCLUSIONS
CONCLUSIONS
In summary, our findings imply a noteworthy upward trend of FMS in Iran, even more than the global prevalence, which suggests a unique Atlas of FMS prevalence in this multi-ethnic population. Despite the highest rate of FMS within Persian and Lor ethnicities, no statistically significant difference was observed among the provinces.
Identifiants
pubmed: 35248009
doi: 10.1186/s12883-022-02609-1
pii: 10.1186/s12883-022-02609-1
pmc: PMC8897924
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
76Informations de copyright
© 2022. The Author(s).
Références
Brain Behav. 2017 Dec 19;8(1):e00899
pubmed: 29568694
Mult Scler Relat Disord. 2020 Aug;43:102178
pubmed: 32417663
Mult Scler Relat Disord. 2019 Aug;33:158-161
pubmed: 31203146
BMC Neurol. 2018 Feb 7;18(1):15
pubmed: 29415659
J Neuroimmunol. 2019 May 15;330:74-80
pubmed: 30836273
BMC Neurol. 2021 Jun 28;21(1):246
pubmed: 34182943
Neurology. 2007 Apr 17;68(16 Suppl 2):S7-12
pubmed: 17438241
Noro Psikiyatr Ars. 2019 Mar;56(1):23-26
pubmed: 30911233
Arq Neuropsiquiatr. 2017 Jul;75(7):451-456
pubmed: 28746432
Acta Neurol Scand. 2019 Mar;139(3):231-237
pubmed: 30412642
Eur J Neurol. 2019 Jan;26(1):27-40
pubmed: 30300457
Iran J Public Health. 2014 Mar;43(3):387-8
pubmed: 25988104
Neuroepidemiology. 2006;27(1):39-44
pubmed: 16804333
Nat Rev Immunol. 2015 Sep 15;15(9):545-58
pubmed: 26250739
Mult Scler Relat Disord. 2018 Feb;20:43-47
pubmed: 29291483
Brain. 2014 Mar;137(Pt 3):770-8
pubmed: 24441172
Mult Scler J Exp Transl Clin. 2020 Oct 12;6(4):2055217320960499
pubmed: 33110617
Eur J Neurol. 2010 Apr;17(4):572-5
pubmed: 20002735
Neuron. 2016 Jun 1;90(5):948-54
pubmed: 27253448
Public Health. 2019 Oct;175:138-144
pubmed: 31476710
Ann Hum Biol. 2004 Mar-Apr;31(2):263-9
pubmed: 15204368
Mult Scler Relat Disord. 2016 Mar;6:54-56
pubmed: 27063623
J Clin Med. 2020 May 02;9(5):
pubmed: 32370288
Am J Epidemiol. 2005 Oct 15;162(8):774-8
pubmed: 16120694
Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):
pubmed: 29440325
Mult Scler Relat Disord. 2019 Feb;28:244-249
pubmed: 30634104
J Clin Neurosci. 2020 Jun;76:145-147
pubmed: 32284288
Mult Scler. 2010 Jun;16(6):694-700
pubmed: 20378663
Neurol Neuroimmunol Neuroinflamm. 2015 Jul 09;2(4):e129
pubmed: 26185776
Lancet Neurol. 2019 May;18(5):459-480
pubmed: 30879893
Eur J Neurol. 2018 Dec;25(12):1425-1431
pubmed: 29956427
Clin Neurol Neurosurg. 2018 Oct;173:144-149
pubmed: 30125837
Nat Rev Neurol. 2019 Aug;15(8):441-445
pubmed: 31086264
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
Iran J Neurol. 2017 Apr 4;16(2):90-95
pubmed: 28761631
J Neurol. 2019 Jan;266(1):278-280
pubmed: 30460446